CA3043640A1 - Human plasma-like medium - Google Patents

Human plasma-like medium Download PDF

Info

Publication number
CA3043640A1
CA3043640A1 CA3043640A CA3043640A CA3043640A1 CA 3043640 A1 CA3043640 A1 CA 3043640A1 CA 3043640 A CA3043640 A CA 3043640A CA 3043640 A CA3043640 A CA 3043640A CA 3043640 A1 CA3043640 A1 CA 3043640A1
Authority
CA
Canada
Prior art keywords
culture medium
cells
concentration
assay
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043640A
Other languages
English (en)
French (fr)
Inventor
David M. Sabatini
Jason Cantor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of CA3043640A1 publication Critical patent/CA3043640A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/32—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of substances in solution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3043640A 2016-11-11 2017-11-13 Human plasma-like medium Pending CA3043640A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421074P 2016-11-11 2016-11-11
US62/421,074 2016-11-11
PCT/US2017/061377 WO2018089928A1 (en) 2016-11-11 2017-11-13 Human plasma-like medium

Publications (1)

Publication Number Publication Date
CA3043640A1 true CA3043640A1 (en) 2018-05-17

Family

ID=62110050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043640A Pending CA3043640A1 (en) 2016-11-11 2017-11-13 Human plasma-like medium

Country Status (6)

Country Link
US (2) US11453858B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538151B1 (cg-RX-API-DMAC7.html)
JP (1) JP7406990B2 (cg-RX-API-DMAC7.html)
CN (1) CN110121359A (cg-RX-API-DMAC7.html)
CA (1) CA3043640A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018089928A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089928A1 (en) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US20220003750A1 (en) * 2018-12-01 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Functional screen for small molecule and monoclonal antibody drug sensitivity in multiple myeloma patients
WO2020264072A1 (en) * 2019-06-25 2020-12-30 Semma Therapeutics, Inc. Enhanced differentiation of beta cells
US12297451B1 (en) * 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN113005082B (zh) * 2019-12-20 2023-08-18 苏州依科赛生物科技股份有限公司 一种t细胞无血清培养基及其应用
CN111334472A (zh) * 2020-03-27 2020-06-26 郑州鲲鹏健康科技有限公司 Pbmc体外3d胶原蛋白水凝胶培养基及其制备方法
CN112029718B (zh) * 2020-09-17 2023-04-07 深圳博雅感知药业有限公司 无血清驯化培养间充质干细胞的方法和所用的培养基
CN113230391A (zh) * 2021-05-13 2021-08-10 杭州医学院 尿酸酶在制备抗肿瘤药物增敏剂中的应用
CN114317446B (zh) * 2021-12-30 2023-12-05 广州康盛生物科技股份有限公司 一种无血清培养基用添加剂及其应用
CN114457149A (zh) * 2022-01-05 2022-05-10 中南大学湘雅二医院 筛选别嘌醇耐受的基因甲基化标志物的应用及检测试剂
CN114634910B (zh) * 2022-03-09 2024-03-08 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种胃癌细胞的培养基及其培养方法
CN116515754B (zh) * 2023-03-17 2024-01-30 创芯国际生物科技(广州)有限公司 一种脂肪肉瘤类器官、培养基及培养方法
CN116751737B (zh) * 2023-08-16 2023-11-14 上海科新生物技术股份有限公司 无血清无蛋白培养基和制备方法及其应用
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them
CN118240744B (zh) * 2024-03-06 2024-11-26 上海迈邦生物科技有限公司 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法
CN118374562B (zh) * 2024-06-26 2024-09-03 山东润德生物科技有限公司 一种用于制备n-乙酰氨基葡萄糖的发酵培养基
CN119286765A (zh) * 2024-12-10 2025-01-10 山东伯桢生物科技有限公司 类器官基础培养基及维持和促进类器官生长的方法
WO2026142011A1 (ko) * 2024-12-27 2026-07-02 주식회사 스웬 생체 샘플 기반 추모 물품 제작 장치 및 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62278980A (ja) * 1986-05-29 1987-12-03 Morinaga & Co Ltd 細胞増殖因子
DE544887T1 (de) 1991-06-17 1994-02-03 Life Technologies Inc Technik zur konzentration von kulturmedien.
ATE205850T1 (de) * 1991-07-05 2001-10-15 Pro Neuron Inc Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
DK0996636T3 (da) 1997-07-23 2005-04-25 Univ Leiden HA-1-antigenet
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
US20070004036A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
US8849577B2 (en) * 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
JP2008109866A (ja) 2006-10-30 2008-05-15 Jms Co Ltd 培地添加剤、この培地添加剤を含む培地、及びこの培地を用いた細胞の培養方法
US20110244502A1 (en) * 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
TWI499412B (zh) 2010-06-16 2015-09-11 亞德生化公司 苯基硫乙酸酯組合物及其使用方法
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
ES2664219T3 (es) 2011-01-28 2018-04-18 Immunic Ag Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria
WO2012125533A1 (en) 2011-03-14 2012-09-20 Wellstat Therapeutics Corporation 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
WO2012141571A1 (en) 2011-04-11 2012-10-18 M Abdullah Jaffar Ali Bin Protein-free culture media products
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
US9034584B2 (en) 2011-07-29 2015-05-19 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells
WO2014017643A1 (ja) 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
CN102994441A (zh) * 2012-09-19 2013-03-27 上海瀚康生物医药科技有限公司 一种细胞培养基及其制备方法和用途
NO2760138T3 (cg-RX-API-DMAC7.html) 2012-10-01 2018-08-04
US20190100725A1 (en) * 2016-03-18 2019-04-04 Institute Of Biophysics, Chinese Academy Of Sciences Cell culture medium and culture medium supplement
WO2018089928A1 (en) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium

Also Published As

Publication number Publication date
EP3538151B1 (en) 2024-06-26
WO2018089928A1 (en) 2018-05-17
US20190352598A1 (en) 2019-11-21
US11453858B2 (en) 2022-09-27
EP3538151A4 (en) 2020-06-10
US20230051644A1 (en) 2023-02-16
CN110121359A (zh) 2019-08-13
JP7406990B2 (ja) 2023-12-28
EP3538151A1 (en) 2019-09-18
JP2020501522A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
US20230051644A1 (en) Human plasma-like medium
Cantor et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase
Koundinya et al. Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers
Groelly et al. Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Pluskal et al. Specific biomarkers for stochastic division patterns and starvation‐induced quiescence under limited glucose levels in fission yeast
Valvezan et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
EP1047938A2 (en) Identification of substances that modify cellular secretory function
TW201726169A (zh) Pd-1訊息抑制劑之併用療法
JP2020501522A5 (cg-RX-API-DMAC7.html)
Bose et al. Absence of activation of DNA repair genes and excellent efficacy of phosphaplatins against human ovarian cancers: implications to treat resistant cancers
Talvas et al. Regulation of protein synthesis by leucine starvation involves distinct mechanisms in mouse C2C12 myoblasts and myotubes
Husseiny et al. The role of B12 deficiency and methionine synthase in methionine-dependent cancer cells
TW200804350A (en) Aryl-substituted quinazolones, and uses thereof
Bornkamm et al. Burkitt’s Lymphoma and Early B Cell Transformation as Paradigms of How Epstein-Barr Virus Overcomes Apoptosis and Ferroptosis
Reichel et al. Fluo‐cAMP is transported by multidrug resistance‐associated protein isoform 4 in rat choroid plexus
El Husseiny et al. Methionine dependence in cancer cells due to lack of B12-dependent methionine synthase activity
El Husseiny et al. The role of B
Apostolova The RING domain of Nse1: roles in Smc5/6 complex stability and genome integrity in human cells
Villarreal Exploring novel roles of metabolic enzymes MTHFD2 and PFKFB3 in cancer genome stability and their potential as anticancer therapeutic targets
Perret et al. Phosphoserine aminotransferase SerC is a central metabolic checkpoint and druggable vulnerability in Mycobacterium tuberculosis
Real Small Molecule Interactions Directed to the Scaffold Kinase Suppressor of Ras Modulate MAPK Signaling in Cancer
Fantozzi Influence of centrosome amplification on the response to chemotherapy in epithelial ovarian cancer
Kraus The role of mitochondrial complex II in cancer cell biology
Gibbs The In Vivo Development of Folate Receptor-Targeted Thymidylate Synthase Inhibitors
HAMRELL et al. Transient induction of phenotypic resistance in human lymphoblastoid cells following sequential use of two antifolates

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250723

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251126